Brookstone Capital Management acquired a new stake in Celgene Co. (NASDAQ:CELG) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,105 shares of the biopharmaceutical company’s stock, valued at approximately $308,000.
Other institutional investors have also recently made changes to their positions in the company. First PREMIER Bank bought a new stake in Celgene in the 3rd quarter valued at about $26,000. Liberty Wealth Management LLC raised its stake in Celgene by 212.8% in the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 200 shares during the period. Massey Quick Simon & CO. LLC bought a new stake in Celgene in the 2nd quarter valued at about $33,000. Lenox Wealth Advisors LLC bought a new stake in Celgene in the 3rd quarter valued at about $37,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Celgene during the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 72.49% of the company’s stock.
A number of research analysts have weighed in on CELG shares. Mizuho reaffirmed a “hold” rating and set a $100.00 target price on shares of Celgene in a report on Sunday. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a report on Tuesday, July 23rd. BidaskClub raised Celgene from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Finally, Cowen reaffirmed a “hold” rating and set a $102.00 target price on shares of Celgene in a report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, seventeen have issued a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $94.60.
Shares of NASDAQ CELG opened at $103.39 on Tuesday. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $103.50. The company has a current ratio of 3.44, a quick ratio of 3.32 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $72.15 billion, a price-to-earnings ratio of 13.59, a PEG ratio of 0.52 and a beta of 1.42. The business has a 50-day moving average of $99.22 and a 200-day moving average of $95.62.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The company had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. During the same quarter in the previous year, the firm earned $2.16 earnings per share. Celgene’s revenue was up 15.4% on a year-over-year basis. On average, analysts predict that Celgene Co. will post 9.96 earnings per share for the current year.
In other news, insider Terrie Curran sold 11,338 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the transaction, the insider now owns 13,493 shares of the company’s stock, valued at $1,325,957.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.39% of the stock is currently owned by insiders.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: How analysts view the yield curve
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.